Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963168 | 1.00 | THRB (0.32) | THRBMEN1KMT2A | |
| Sulfuric Acid SCHEMBL3969224 | 0.87 | KDM4E (0.32) | — | |
| SCHEMBL8187101 | 0.80 | — | — | |
| SCHEMBL14805845 | 0.80 | FUCA1 (0.34) | — | |
| SCHEMBL23463642 | 0.80 | FUCA1 (0.30) | — | |
| SCHEMBL24429386 | 0.80 | FUCA1 (0.30) | — | |
| SCHEMBL14504634 | 0.80 | LMNA (0.32) | — | |
| SCHEMBL24549448 | 0.78 | — | — | |
| SCHEMBL22540215 | 0.78 | — | — | |
| SCHEMBL24234606 | 0.76 | EPHX1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219919-A1 | LITHIUM EXTRACTION WITH CROWN ETHERS | ORCA HOLDINGS, LLC | 2023-07-13 | — | — | US | disclosed |
| EP-1517911-B1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | KEPPLER PROF DR DR BERNHARD K (AT) | 2009-07-29 | — | — | EP | disclosed |
| US-7057059-B2 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH | 2005-06-30 | — | — | US | disclosed |
| EP-1517911-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | Faustus Forschungs Cie. Translational Cancer Research GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003106469-A1 | TUMOUR-INHIBITING PLATINUM (II) OXALATE COMPLEXES | FAUSTUS FORSCHUNGS CIE. TRANSLATIONAL CANCER RESEARCH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219919-A1 | LITHIUM EXTRACTION WITH CROWN ETHERS | LCLAT1, LCT, IGF2R | THRB 1674/4885MEN1 2987/4885KMT2A 102/4885 |
| US-20050143455-A1 | Tumor-inhibiting platinum (II) oxalate complexes | OXGR1, OAT, OXA1L | THRB 596/4885MEN1 1173/4885KMT2A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.